StockData
Alkermes plc. logo

Alkermes plc. (ALKS) stock

ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30208% above fair value
$45.45−1.08 (-2.32%)

Close on Nov 17, 2026Market cap $7.62BP/E 119.6Yield –

Alkermes net income

Net income is the profit left for shareholders after every expense, interest and tax.

Alkermes's net income for the twelve months ending Jun 30, 2026 was $66.12M, down 81.0% year over year. For fiscal 2025 it was $241.66M, down 34.2% from the year before. The highest annual figure on record is $367.07M in fiscal 2024.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$241.66M-34.2%
FY2024Dec 31, 2024$367.07M+3.2%
FY2023Dec 31, 2023$355.76M–
FY2022Dec 31, 2022-$158.27M–
FY2021Dec 31, 2021-$48.17M–
FY2020Dec 31, 2020-$110.86M–
FY2019Dec 31, 2019-$196.62M–
FY2018Dec 31, 2018-$139.31M–
FY2017Dec 31, 2017-$157.95M–
FY2016Dec 31, 2016-$208.44M–
FY2015Dec 31, 2015-$227.16M-1009.3%
FY2013Mar 31, 2013$24.98M–
FY2012Mar 31, 2012-$113.68M–
FY2011Mar 31, 2011-$45.54M–
FY2010Mar 31, 2010-$39.63M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$501.00K-99.4%
Q1 FY2026Mar 31, 2026-$66.48M-395.9%
Q4 FY2025Dec 31, 2025$49.34M-66.3%
Q3 FY2025Sep 30, 2025$82.76M-10.4%
Q2 FY2025Jun 30, 2025$87.10M-4.7%
Q1 FY2025Mar 31, 2025$22.46M-39.0%
Q4 FY2024Dec 31, 2024$146.50M+29.9%
Q3 FY2024Sep 30, 2024$92.38M+93.4%
Q2 FY2024Jun 30, 2024$91.36M-61.5%
Q1 FY2024Mar 31, 2024$36.83M–
Q4 FY2023Dec 31, 2023$112.78M–
Q3 FY2023Sep 30, 2023$47.76M–
Q2 FY2023Jun 30, 2023$237.07M–
Q1 FY2023Mar 31, 2023-$41.85M–
Q4 FY2022Dec 31, 2022-$28.25M-3336.4%
Q3 FY2022Sep 30, 2022-$63.97M–
Q2 FY2022Jun 30, 2022-$30.14M-1374.8%
Q1 FY2022Mar 31, 2022-$35.90M–
Q4 FY2021Dec 31, 2021$873.00K–
Q3 FY2021Sep 30, 2021-$28.99M–
Q2 FY2021Jun 30, 2021$2.36M–
Q1 FY2021Mar 31, 2021-$22.42M–
Q4 FY2020Dec 31, 2020-$42.64M–
Q3 FY2020Sep 30, 2020-$134.00K–
Q2 FY2020Jun 30, 2020-$29.43M–
Q1 FY2020Mar 31, 2020-$38.65M–
Q4 FY2019Dec 31, 2019-$5.35M–
Q3 FY2019Sep 30, 2019-$52.88M–
Q2 FY2019Jun 30, 2019-$41.99M–
Q1 FY2019Mar 31, 2019-$96.40M–
Q4 FY2018Dec 31, 2018-$9.71M–
Q3 FY2018Sep 30, 2018-$34.44M–
Q2 FY2018Jun 30, 2018-$32.65M–
Q1 FY2018Mar 31, 2018-$62.51M–

More Alkermes figures

See a number that looks wrong?